On December 7th, according to Zhongzheng News and Zhongzheng Network (Wang Luo), the long-acting growth hormone - Yipei Growth Hormone Injection (trade name: Yipei Sheng) independently developed by Tebao Biotechnology ®） Successfully included in the medical insurance catalog through negotiation.

This entry into medical insurance has profound significance for TeBao Biotechnology. It not only marks the product's qualification for national market access, but also verifies a core business proposition in the context of medical insurance negotiations: differentiated innovative drugs with significant clinical advantages and higher safety can only gain recognition and support.

Yi Peisheng ® The smooth entry into the market is due to its solid "quality hard power", especially its breakthrough innovation and safety upgrade in molecular design, which has built a differentiation advantage that is difficult to replicate for the product. In the field of pediatric medication, the ability to achieve higher "safety" through technological means is itself a highly valuable innovation. TeBao Biotechnology has overcome this challenge through research and development innovation, which also indicates that only products that truly solve clinical pain points can achieve significant development.

TeBao Biotechnology has been deeply involved in the field of long-acting protein drugs for many years, and its core competitiveness lies in its ability to handle high barrier biotechnology and accurately translate it into clinical benefits that directly address user pain points. Reviewing the development process of the enterprise, from the deep cultivation of the clinical cure of hepatitis B "Paigebin" ®”， Up to now, Yipeisheng, who cares for children's growth ®”， TeBao Biology has always been practicing a simple value system: to persist in doing difficult but right things.

In the field of hepatitis B, the "Everest Project" supported by Tebo Biology has brought hope for clinical cure to countless patients; In the field of pediatrics, Yipeisheng ® Carrying the same mission - to enable more children with dwarfism not only to "afford" long-acting growth hormone, but also to "use it well and safely".

This time, Yipei Sheng ® Inclusion in medical insurance will significantly improve the accessibility of drugs, reduce the economic burden on patients' families, and enable high-quality innovative drugs to "fly into ordinary people's homes". The adherence of enterprises to high standards and preservative free production processes ensures that drugs maintain safe and reliable quality and efficacy while improving accessibility. The unity of "accessibility" and "high quality" is the best footnote to TeBao Biotechnology's commitment to "patient-centered".

Looking ahead to 2026, with the implementation of the new version of the medical insurance catalog, Yipei Sheng ® Expected to succeed Pygman ® Afterwards, it became the second engine driving the growth of TeBao Biotechnology's performance. For the capital market, a company that always focuses on technological innovation to solve practical clinical problems has a clear long-term growth logic.